HALO - HALOZYME THERAPEUTICS, INC.

68.41
-1.160   -1.696%

Share volume: 1,542,621
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$69.57
-1.16
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
48%
Profitability 51%
Dept financing 24%
Liquidity 72%
Performance 45%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.27%
1 Month
8.83%
3 Months
-4.04%
6 Months
4.01%
1 Year
17.52%
2 Year
76.72%
Key data
Stock price
$68.41
P/E Ratio 
24.97
DAY RANGE
$68.24 - $70.02
EPS 
$2.64
52 WEEK RANGE
$47.50 - $82.22
52 WEEK CHANGE
$17.12
MARKET CAP 
7.914 B
YIELD 
N/A
SHARES OUTSTANDING 
118.017 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,382,348
AVERAGE 30 VOLUME 
$1,361,194
Company detail
CEO: Helen I. Torley
Region: US
Website: halozyme.com
Employees: 390
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)

Recent news